Rick A. Vreman

1.1k total citations
53 papers, 682 citations indexed

About

Rick A. Vreman is a scholar working on Economics and Econometrics, Physiology and General Health Professions. According to data from OpenAlex, Rick A. Vreman has authored 53 papers receiving a total of 682 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Economics and Econometrics, 10 papers in Physiology and 7 papers in General Health Professions. Recurrent topics in Rick A. Vreman's work include Health Systems, Economic Evaluations, Quality of Life (38 papers), Pharmaceutical Economics and Policy (30 papers) and Biomedical Ethics and Regulation (9 papers). Rick A. Vreman is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (38 papers), Pharmaceutical Economics and Policy (30 papers) and Biomedical Ethics and Regulation (9 papers). Rick A. Vreman collaborates with scholars based in Netherlands, United States and United Kingdom. Rick A. Vreman's co-authors include Wim Goettsch, Aukje K. Mantel‐Teeuwisse, Hubert G. M. Leufkens, Anke M. Hövels, Aaron S. Kesselheim, Joris C. Verster, Travis C. Porco, Berend Olivier, Thomas Roth and Suzanne de Klerk and has published in prestigious journals such as PLoS ONE, European Heart Journal and Psychopharmacology.

In The Last Decade

Rick A. Vreman

51 papers receiving 667 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rick A. Vreman Netherlands 15 378 99 83 78 71 53 682
Graham Wheeler United Kingdom 10 164 0.4× 79 0.8× 65 0.8× 49 0.6× 125 1.8× 31 847
Rukmini Rajagopalan United States 18 141 0.4× 94 0.9× 52 0.6× 153 2.0× 41 0.6× 47 1.3k
Virginie Hivert France 11 117 0.3× 143 1.4× 105 1.3× 88 1.1× 119 1.7× 17 624
Deirdre Weymann Canada 13 226 0.6× 17 0.2× 51 0.6× 33 0.4× 75 1.1× 34 561
Lang’o Odondi United Kingdom 9 131 0.3× 28 0.3× 50 0.6× 40 0.5× 54 0.8× 11 573
Eline van Overbeeke Belgium 14 322 0.9× 57 0.6× 151 1.8× 38 0.5× 85 1.2× 26 674
Prasun Subedi United States 10 142 0.4× 35 0.4× 56 0.7× 47 0.6× 27 0.4× 22 434
Anja Jacobs Germany 19 93 0.2× 80 0.8× 116 1.4× 98 1.3× 99 1.4× 39 978
Jacqueline Corrigan‐Curay United States 9 148 0.4× 33 0.3× 32 0.4× 42 0.5× 60 0.8× 13 616
Shiraz R. Gupta United States 15 237 0.6× 67 0.7× 52 0.6× 79 1.0× 41 0.6× 20 1.2k

Countries citing papers authored by Rick A. Vreman

Since Specialization
Citations

This map shows the geographic impact of Rick A. Vreman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rick A. Vreman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rick A. Vreman more than expected).

Fields of papers citing papers by Rick A. Vreman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rick A. Vreman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rick A. Vreman. The network helps show where Rick A. Vreman may publish in the future.

Co-authorship network of co-authors of Rick A. Vreman

This figure shows the co-authorship network connecting the top 25 collaborators of Rick A. Vreman. A scholar is included among the top collaborators of Rick A. Vreman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rick A. Vreman. Rick A. Vreman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vreman, Rick A., et al.. (2024). Agreement about Availability of Alternative Treatments for Innovative Drugs Assessed by the EMA and HTA Organizations. Clinical Pharmacology & Therapeutics. 116(1). 136–146. 2 indexed citations
2.
Leufkens, Hubert G.M., et al.. (2024). Stimulating development of innovative medicines in the European Union: does a new definition for unmet medical need add value?. Drug Discovery Today. 30(1). 104251–104251. 1 indexed citations
3.
Wang, Junfeng, Gema García-Sáez, M. Elena Hernando, et al.. (2024). A literature review of quality assessment and applicability to HTA of risk prediction models of coronary heart disease in patients with diabetes. Diabetes Research and Clinical Practice. 209. 111574–111574. 1 indexed citations
4.
Vreman, Rick A., Anna Zawada, Magdalena Zielińska, et al.. (2023). Synergy between health technology assessments and clinical guidelines for multiple sclerosis. Clinical and Translational Science. 16(5). 835–849. 6 indexed citations
5.
Vreman, Rick A., Junfeng Wang, Marie L. De Bruin, et al.. (2023). Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts. BMJ Open. 13(8). e072309–e072309. 10 indexed citations
6.
Vreman, Rick A., et al.. (2023). The Beneluxa Initiative domain task force health technology assessment: a comparison of member countries’ past health technology assessments. International Journal of Technology Assessment in Health Care. 39(1). e44–e44. 2 indexed citations
7.
Vreman, Rick A., et al.. (2023). Response to uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group – author’s reply. International Journal of Technology Assessment in Health Care. 40(1). e1–e1. 1 indexed citations
8.
Vreman, Rick A., et al.. (2022). When Reality Does Not Meet Expectations—Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs. International Journal of Environmental Research and Public Health. 20(1). 340–340. 9 indexed citations
9.
Vreman, Rick A., et al.. (2022). Addressing uncertainty in relative effectiveness assessments by HTA organizations. International Journal of Technology Assessment in Health Care. 38(1). e17–e17. 7 indexed citations
10.
11.
Eichler, Hans‐Georg, Róisín Adams, Peter Arlett, et al.. (2021). Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements. International Journal of Technology Assessment in Health Care. 37(1). e83–e83. 15 indexed citations
12.
13.
Vreman, Rick A., et al.. (2020). The Application and Implications of Novel Deterministic Sensitivity Analysis Methods. PharmacoEconomics. 39(1). 1–17. 21 indexed citations
14.
Vreman, Rick A., et al.. (2020). Increasing the information provided by probabilistic sensitivity analysis: The relative density plot. Cost Effectiveness and Resource Allocation. 18(1). 54–54. 2 indexed citations
15.
Vreman, Rick A., et al.. (2020). Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis. International Journal of Environmental Research and Public Health. 17(22). 8309–8309. 27 indexed citations
16.
Vreman, Rick A., Svetlana V. Belitser, Anke M. Hövels, et al.. (2020). Efficacy gap between phase II and subsequent phase III studies in oncology. British Journal of Clinical Pharmacology. 86(7). 1306–1313. 10 indexed citations
17.
Vreman, Rick A., Huseyin Naci, Wim Goettsch, et al.. (2020). Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. Clinical Pharmacology & Therapeutics. 108(2). 350–357. 52 indexed citations
18.
Vreman, Rick A., Jarno Hoekman, Hubert G. M. Leufkens, et al.. (2020). The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. International Journal of Health Policy and Management. 11(5). 642–650. 12 indexed citations
19.
Vreman, Rick A., et al.. (2019). Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. Applied Health Economics and Health Policy. 17(6). 883–893. 14 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Graham Wheeler Breakdown of academic impact, for papers by Rukmini Rajagopalan Breakdown of academic impact, for papers by Virginie Hivert Breakdown of academic impact, for papers by Deirdre Weymann Breakdown of academic impact, for papers by Lang’o Odondi Breakdown of academic impact, for papers by Eline van Overbeeke Breakdown of academic impact, for papers by Prasun Subedi Breakdown of academic impact, for papers by Anja Jacobs Breakdown of academic impact, for papers by Jacqueline Corrigan‐Curay Breakdown of academic impact, for papers by Shiraz R. Gupta
Rankless by CCL
2026